Karen Nugent

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Bioverativ Therapeutics Inc., Biogen Hemophilia Inc., Biogen Idec Hemophilia Inc.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karen Nugent. Retrieved from https://idiyas.com/inventor/karen-nugent

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 12.0

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Owlswick, GB (2018 - 2021)
Princes Risborough, GB (2015 - 2022)

Company Filing History:

4 out of 76

Bioverativ Therapeutics Inc.

patents

1 out of 2

Biogen Hemophilia Inc.

patents

1 out of 5

Biogen Idec Hemophilia Inc.

patents

Years Active: 2015-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2025-01-07),

2. 11266720 - Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof (2022-03-08),

3. 10881742 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2021-01-05),

4. 10010622 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2018-07-03),

5. 9241978 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof (2016-01-26),

6. 9050318 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof (2015-06-09),

Title: Inventor Spotlight: Karen Nugent - Pioneering Factor VIII Innovations

Introduction: Meet Karen Nugent, a brilliant inventor hailing from Princes Risborough, GB, who has made significant contributions to the field of Factor VIII research through her innovative patents.

Latest Patents: Karen Nugent's latest patents revolve around Factor VIII-FC chimeric and hybrid polypeptides, showcasing her expertise in developing methods for administering Factor VIII, as well as creating chimeric and hybrid polypeptides comprising Factor VIII. These patents encompass polynucleotides encoding such polypeptides, cells with these polynucleotides, and techniques for producing these innovative molecules using said cells.

Career Highlights: With a total of 5 patents to her name, Karen Nugent has been a key figure in companies like Bioverativ Therapeutics Inc. and Biogen Idec Hemophilia Inc., where she has played a crucial role in advancing research and development in the field of hemophilia treatments. Her dedication to improving Factor VIII therapies has significantly impacted the medical and scientific communities.

Collaborations: Throughout her career, Karen Nugent has collaborated with esteemed professionals such as Jennifer A Dumont and Susan C Low, showcasing her ability to work effectively in teams to drive innovation and progress in the pharmaceutical industry.

Conclusion: Karen Nugent's groundbreaking work in the realm of Factor VIII-FC chimeric and hybrid polypeptides underscores her commitment to pushing the boundaries of scientific discovery and improving the quality of life for individuals with hemophilia. Her contributions stand as a testament to her ingenuity and dedication to advancing medical research.

Profile summary based on public USPTO records.